CN114901665B - 三唑并三嗪衍生物在治疗疾病中的用途 - Google Patents

三唑并三嗪衍生物在治疗疾病中的用途 Download PDF

Info

Publication number
CN114901665B
CN114901665B CN202080089936.XA CN202080089936A CN114901665B CN 114901665 B CN114901665 B CN 114901665B CN 202080089936 A CN202080089936 A CN 202080089936A CN 114901665 B CN114901665 B CN 114901665B
Authority
CN
China
Prior art keywords
compound
test
optionally substituted
compounds
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080089936.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114901665A (zh
Inventor
孙三兴
陈正树
叶进启
赵龙
胡崇波
杨勇
管峰
潘姝花
胡宁
潘婷婷
宋国伟
侯方杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Chunhe Pharmaceutical Technology Co ltd
Original Assignee
Zhejiang Chunhe Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Chunhe Pharmaceutical Technology Co ltd filed Critical Zhejiang Chunhe Pharmaceutical Technology Co ltd
Publication of CN114901665A publication Critical patent/CN114901665A/zh
Application granted granted Critical
Publication of CN114901665B publication Critical patent/CN114901665B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080089936.XA 2019-12-26 2020-12-25 三唑并三嗪衍生物在治疗疾病中的用途 Active CN114901665B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911364028 2019-12-26
CN2019113640282 2019-12-26
PCT/CN2020/139690 WO2021129843A1 (zh) 2019-12-26 2020-12-25 三唑并三嗪衍生物在治疗疾病中的用途

Publications (2)

Publication Number Publication Date
CN114901665A CN114901665A (zh) 2022-08-12
CN114901665B true CN114901665B (zh) 2025-02-18

Family

ID=76573699

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080089936.XA Active CN114901665B (zh) 2019-12-26 2020-12-25 三唑并三嗪衍生物在治疗疾病中的用途

Country Status (5)

Country Link
US (1) US20230048888A1 (enExample)
EP (1) EP4083044A4 (enExample)
JP (1) JP2023508182A (enExample)
CN (1) CN114901665B (enExample)
WO (1) WO2021129843A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056879A (zh) * 1990-05-29 1991-12-11 帝国化学工业公司 吡咯衍生物及其制备方法
CN111051309A (zh) * 2018-06-26 2020-04-21 浙江春禾医药科技有限公司 可用作a2a受体拮抗剂的三唑并三嗪衍生物
CN111164084A (zh) * 2018-06-26 2020-05-15 浙江春禾医药科技有限公司 可用作a2a受体拮抗剂的三唑并三嗪衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356894A (en) * 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
GB9111131D0 (en) * 1991-05-23 1991-07-17 Ici Plc Heterocyclic compounds
GB9125002D0 (en) * 1991-11-25 1992-01-22 Ici Plc Azole derivatives
CA2148502A1 (en) * 1993-09-06 1995-03-16 Fumio Suzuki Antidepressants
JP4228048B2 (ja) 2000-10-09 2009-02-25 ピーオーダブリューエムアールアイ リミテッド 神経変性障害の検出方法
DE60231386D1 (de) * 2001-04-09 2009-04-16 Neurosearch As Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
IL161573A0 (en) * 2001-11-30 2004-09-27 Schering Corp [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2004092173A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2018013951A1 (en) * 2016-07-15 2018-01-18 Northwestern University Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
TWI801372B (zh) * 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056879A (zh) * 1990-05-29 1991-12-11 帝国化学工业公司 吡咯衍生物及其制备方法
CN111051309A (zh) * 2018-06-26 2020-04-21 浙江春禾医药科技有限公司 可用作a2a受体拮抗剂的三唑并三嗪衍生物
CN111164084A (zh) * 2018-06-26 2020-05-15 浙江春禾医药科技有限公司 可用作a2a受体拮抗剂的三唑并三嗪衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Novel adenosine A2Areceptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space;Peter W. R. Caulkett et al.;HEJ. CHEM. SOC. PERKIN TRANS.;19950101;第1卷;第3427-3428页，表1 *
Targeting adenosine for cancer immunotherapy;Robert D. Leone et al.;JOURNAL FOR IMMUNOTHERAPY OF CANCER;20180618;第6卷;第3页 *
W. Sihver et al..Binding of tritiated and radioiodinated ZM241,385 to brain A2A adenosine receptors.Nuclear Medicine and Biology.2004,第31卷第173页第1-2段，第174页fig 1，第175页右栏第2段. *

Also Published As

Publication number Publication date
EP4083044A4 (en) 2024-03-27
JP2023508182A (ja) 2023-03-01
US20230048888A1 (en) 2023-02-16
CN114901665A (zh) 2022-08-12
EP4083044A1 (en) 2022-11-02
WO2021129843A1 (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
JP7631434B2 (ja) セレブロン（ｃｒｂｎ）に対するリガンド
CA2969090C (en) Triazolopyrimidine compounds and uses thereof
AU2019223014B2 (en) Combination therapy with apilimod and glutamatergic agents
EP4034132B1 (en) Erk5 degraders as therapeutics in cancer and inflammatory diseases
CN112020358A (zh) 诱导蛋白质选择性降解的小分子及其用途
BR112020019189A2 (pt) produtos de combinação que compreendem inibidor de bcl-2 ou inibidor duplo de bcl-2/bcl-xl e inibidor de btk e usos terapêuticos dos mesmos
AU2019202922A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
JP6014695B2 (ja) 癌および他の疾患または障害の治療のための医薬組成物
JP2019524872A (ja) 癌の治療に有用なイミダゾピリミジン化合物
JP2019522049A (ja) トリアゾロピリジン化合物及びその使用
CA3021550A1 (en) Pyrazolopyrimidine compounds, compositions comprising the same and their use as tyrosine kinase inhibitors
CA3067695A1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP4370126A1 (en) Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
JP2025529321A (ja) Ｃｄｋ４キナーゼ阻害剤として使用される化合物及びその応用
JP2024526305A (ja) Ｌｒｒｋ２の野生型および変異体形態の分解剤ならびにその使用
JP2024511466A (ja) Ａｌｋ－５阻害剤及びその使用
CN120309636A (zh) 取代桥环类抑制剂及其制备方法和应用
JP2015534990A (ja) 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
CN114901665B (zh) 三唑并三嗪衍生物在治疗疾病中的用途
US20230255933A1 (en) Antiviral use of fabp4 modulating compounds
EP3364976A1 (en) Piperazinyl norbenzomorphan compounds and methods for using the same
US12138243B2 (en) Antiviral use of FABP4 modulating compounds
US20230226196A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
CN118666846A (zh) 苯甲羰基吲哚类衍生物及其用途
CN118632847A (zh) 用作cdk4激酶抑制剂的化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant